Understanding the Importance of Smart Drugs in Renal Cell Carcinoma
- 30 April 2006
- journal article
- review article
- Published by Elsevier BV in European Urology
- Vol. 49 (4), 633-643
- https://doi.org/10.1016/j.eururo.2006.01.016
Abstract
No abstract availableThis publication has 84 references indexed in Scilit:
- Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical ResultsJournal of Clinical Oncology, 2005
- Mammalian Target of Rapamycin InhibitionClinical Cancer Research, 2004
- The Genetic Basis of Cancer of the KidneyJournal of Urology, 2003
- Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma CellsOnline Journal of Public Health Informatics, 2003
- Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinomaCancer, 2003
- Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine KinaseJournal of Medicinal Chemistry, 2003
- Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activityOncogene, 1999
- Failure of blood-island formation and vasculogenesis in Flk-1-deficient miceNature, 1995
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993
- Von Hippel–Lindau disease maps to the region of chromosome 3 associated with renal cell carcinomaNature, 1988